Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3.
- DOI
- 10.1158/0008-5472.can-04-0006
- Published
- 2004 May 15
- Container
- Cancer research
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1158/0008-5472.can-04-0006,
title = {Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3.},
author = {George P and Bali P and Cohen P and Tao J and Guo F and Sigua C and Vishvanath A and Fiskus W and Scuto A and Annavarapu S and Moscinski L and Bhalla K},
year = {2004},
journal = {Cancer research},
doi = {10.1158/0008-5472.can-04-0006},
url = {https://doi.org/10.1158/0008-5472.can-04-0006}
}RIS
TY - JOUR TI - Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3. AU - George P AU - Bali P AU - Cohen P AU - Tao J AU - Guo F AU - Sigua C AU - Vishvanath A AU - Fiskus W AU - Scuto A AU - Annavarapu S AU - Moscinski L AU - Bhalla K PY - 2004 JO - Cancer research DO - 10.1158/0008-5472.can-04-0006 UR - https://doi.org/10.1158/0008-5472.can-04-0006 ER -
APA
P, G., P, B., P, C., J, T., F, G., C, S., A, V., W, F., A, S., S, A., L, M., & K, B. (2004). Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3.. Cancer research. https://doi.org/10.1158/0008-5472.can-04-0006
Source records
- pubmed · retrieved 2026-09-26T08:57:35.646Z